Phenindione - Misplaced Pages

This is the current revision of this page, as edited by حسن علي البط (talk | contribs) at 20:29, 16 July 2024 (removed Category:Indandiones; added Category:1,3-Indandiones using HotCat). The present address (URL) is a permanent link to this version.

Revision as of 20:29, 16 July 2024 by حسن علي البط (talk | contribs) (removed Category:Indandiones; added Category:1,3-Indandiones using HotCat)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Chemical compound Pharmaceutical compound

Phenindione
Clinical data

AHFS/Drugs.com	International Drug Names
Pregnancy category	AU: D Passes into breast milk
Routes of administration	Oral
ATC code	B01AA02 (WHO)
Pharmacokinetic data
Protein binding	88%
Elimination half-life	5 to 10 hours
Identifiers
IUPAC name 2-phenyl-1H-indene-1,3(2H)-dione
CAS Number	83-12-5
PubChem CID	4760
IUPHAR/BPS	6838
DrugBank	DB00498
ChemSpider	4596
UNII	5M7Y6274ZE
KEGG	D08354
ChEBI	CHEBI:8066
ChEMBL	ChEMBL711
CompTox Dashboard (EPA)	DTXSID5023453
ECHA InfoCard	100.001.323
Chemical and physical data
Formula	C₁₅H₁₀O₂
Molar mass	222.243 g·mol
3D model (JSmol)	Interactive image
SMILES O=C2c1ccccc1C(=O)C2c3ccccc3
InChI InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H Key:NFBAXHOPROOJAW-UHFFFAOYSA-N
(verify)

Phenindione is an anticoagulant which functions as a Vitamin K antagonist.

Phenindione was introduced in the early 1950s. It acts similar to warfarin, but it has been associated with hypersensitivity reactions, so it is rarely used and warfarin is preferred.

References

Naisbitt DJ, Farrell J, Chamberlain PJ, Hopkins JE, Berry NG, Pirmohamed M, Park BK (June 2005). "Characterization of the T-cell response in a patient with phenindione hypersensitivity". The Journal of Pharmacology and Experimental Therapeutics. 313 (3): 1058–65. doi:10.1124/jpet.105.083758. PMID 15743920. S2CID 17052792.
Sweetman SC, ed. (2009). Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. "Phenindione", p. 1369.

External links

Diseases Database (DDB): 30536

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab Eptifibatide Orbofiban Roxifiban Sibrafiban Tirofiban
ADP receptor/P2Y₁₂ inhibitors	Thienopyridines Clopidogrel Prasugrel Ticlopidine Nucleotide/nucleoside analogs Cangrelor Elinogrel Ticagrelor
Prostaglandin analogue (PGI2)	Beraprost Iloprost Prostacyclin Treprostinil
COX inhibitors	Acetylsalicylic acid/Aspirin Aloxiprin Carbasalate calcium Indobufen Triflusal
Thromboxane inhibitors	Thromboxane synthase inhibitors Dipyridamole (+ aspirin) Picotamide Terbogrel Receptor antagonists Terbogrel Terutroban
Phosphodiesterase inhibitors	Cilostazol Dipyridamole Triflusal
Other	Cloricromen Ditazole Vorapaxar

Anticoagulants

Vitamin K antagonists
(inhibit II, VII, IX, X)

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bind antithrombin)	Low-molecular-weight heparin Bemiparin Certoparin Dalteparin Enoxaparin Nadroparin Parnaparin Reviparin Tinzaparin Oligosaccharides Fondaparinux Idraparinux Heparinoids Danaparoid Dermatan sulfate Sulodexide
Direct Xa inhibitors ("xabans")	Apixaban Betrixaban Darexaban Edoxaban Otamixaban Rivaroxaban

Direct thrombin (IIa) inhibitors

Other

Thrombolytic drugs/
fibrinolytics

Non-medicinal

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This drug article relating to the blood and blood forming organs is a stub. You can help Misplaced Pages by expanding it.

Categories: